Emerging Market Earnings Roundup: China Surpasses Japan As AstraZeneca’s Second Largest Market (Part 4)
This article was originally published in PharmAsia News
Executive Summary
China is now AstraZeneca’s second largest market where it out grew multinational peers including Pfizer in the first quarter.
You may also be interested in...
AstraZeneca’s Soriot Says Mega-Mergers Can Work, But Is Hush Hush On Pfizer
AstraZeneca did not address rumors it has become an acquisition target of Pfizer during its first quarter conference call. CEO Soriot did say that some mega-mergers can work, but such deals have to be evaluated on a case-by-case basis.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.